Down-regulation of β-catenin by activated p53

Molecular and Cellular Biology

Volumn 21, Issue 20, 2001, Pages 6768-6781

  Sadot, E ^a   Geiger, B ^a   Oren, M ^a   Ben Ze'ev, A ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEASOME; PROTEIN P53;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSACTIVATION;

ANIMALS; BETA CATENIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE; CELL NUCLEUS; CISPLATIN; CYSTEINE ENDOPEPTIDASES; CYTOSKELETAL PROTEINS; CYTOSKELETON; DOWN-REGULATION; DOXORUBICIN; FIBROBLASTS; GENES, DOMINANT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASES; HUMANS; LUCIFERASES; MICE; MICROSCOPY, FLUORESCENCE; MODELS, GENETIC; MULTIENZYME COMPLEXES; MUTATION; PLASMIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 0034808019     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.20.6768-6781.2001     Document Type: Article

References (95)

1. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53
2. Cytomechanics of cadherin-mediated cell-cell adhesion
3. Maintenance of genomic integrity by p53: Complementary roles for activated and non-activated p53
4. Stress signals utilize multiple pathways to stabilize p53
5. Regulation of p53 stability
6. Recruitment of p300/CBP in p53-dependent signal pathways
7. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
8. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression
9. Functional interaction of beta-catenin with the transcription factor LEF-1
10. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer
11. Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of beta-catenin
12. The p53 pathway and apoptosis
13. A common human skin tumour is caused by activating mutations in beta-catenin
14. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
15. Excess β-catenin promotes accumulation of transcriptionally active p53
16. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas
17. Multiple genetic alterations in distal and proximal colorectal cancer
18. Regulation of p53 downstream genes
19. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
20. Wild-type p53 can inhibit oncogene-mediated focus formation
21. HOS, human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin
22. Beta-catenin mutation in carcinoma of the uterine endo metrium
23. Beta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome
24. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma
25. De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin
26. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression
27. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene
28. Monoclonal antibodies specific for simian virus 40 tumor antigens
29. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell
30. Cell type-specific inhibition of p53-mediated apoptosis by mdm2
31. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
32. Identification of c-MYC as a target of the APC pathway
33. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates
34. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1
35. The dual role model for p53 in maintaining genomic integrity
36. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma
37. Design and construction of an optimal illumination system for quantitative wide-field multi-dimensional microscopy
38. Regulation of beta-catenin signaling in the Wnt pathway
39. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients
40. Lessons from hereditary colorectal cancer
41. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin
42. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene
43. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors
44. Sequence of molecular genetic events in colorectal tumorigenesis
45. p53, the cellular gatekeeper for growth and division
46. Beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation
47. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein
48. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas
49. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins
50. Viral oncoproteins discriminate between p53 and the p53 homolog p73
51. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses
52. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway
53. Regulation of lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP/p300
54. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis
55. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
56. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos
57. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
58. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein
59. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine requires p53
60. Mutations in the p53 gene occur in diverse human tumour types
61. Regulation of the p53 tumor suppressor protein
62. Exogenous expression of beta-catenin regulates contact inhibition, anchorage independent growth, anoikis, and radiation-induced cell cycle arrest
63. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
64. Beta-catenin as oncogene: The smoking gun
65. The oncogenic activation of beta-catenin
66. Wnt signaling and cancer
67. Hepatocellular carcinoraa in WHV/N-myc2 transgenic mice: Oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles
68. TCF transcription factors: Molecular switches in carcinogenesis
69. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and rumor suppression
70. Stabilization of beta-catenin by genetic defects in melanoma cell lines
71. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system
72. The ARF/p53 pathway
73. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway
74. Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin
75. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers
76. The cellular response to p53: The decision between life and death
77. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer
78. Inhibition of viral and cellular promoters by human wild-type p53
79. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression
80. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
81. Proteolytic cleavage of beta-catenin by caspases: An in vitro analysis
82. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF
83. Beta-catenin mutations in human prostate cancer
84. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
85. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53
86. Transcriptional cross talk between NF-kappaB and p53
87. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas
88. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro
89. Beta-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours
90. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene
91. The axis-inducing activity, stability, and subcellular distribution of betacatenin is regulated in Xenopus embryos by glycogen synthase kinase 3
92. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
93. Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin
94. Plakoglobin and β-catenin: Protein interactions, regulation and biological roles
95. Sporadic medullo-blastomas contain oncogenic beta-catenin mutations